International Isotopes, Inc. engages in the manufacture of nuclear medicine calibration and reference standards cobalt tele therapy sources, as well as radioisotopes and radiochemical for medical research and clinical devices. The company is headquartered in Idaho Falls, Idaho and currently employs 41 full-time employees. The firm's segments include Theranostics Products, Cobalt Products, Nuclear Medicine Standards, Medical Device Products and Fluorine Products. Theranostics Products segment includes production and distribution of its generic sodium iodide I-131 drug product for the treatment of hyperthyroidism and carcinoma of the thyroid. Cobalt Products segment includes the production of bulk cobalt (cobalt-60), fabrication of cobalt capsules for radiation therapy and various industrial applications. Nuclear Medicine Standards segment consists of the manufacture of sources and standards associated with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging. Fluorine Products segment is involved in the production of small-scale qualification samples of high-purity fluoride gas for various industrial applications. The company is working to launch the RadVent brand of medical devices.
Follow-Up Questions
What is International Isotopes Inc (INIS)'s P/E Ratio?
The P/E ratio of International Isotopes Inc is 3472.4232
Who is the CEO of International Isotopes Inc?
Mr. Shahe Bagerdjian is the President of International Isotopes Inc, joining the firm since 2023.
What is the price performance of INIS stock?
The current price of INIS is $0.055, it has decreased 0% in the last trading day.
What are the primary business themes or industries for International Isotopes Inc?
International Isotopes Inc belongs to Life Sciences Tools & Services industry and the sector is Health Care
What is International Isotopes Inc market cap?
International Isotopes Inc's current market cap is $29.0M
